A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. SUDESH KUMAR				
AGE/ GENDER	: 43 YRS/MALE	PATI	ENT ID	: 1605013	
COLLECTED BY	:	REG.	NO./LAB NO.	: 122409070011	
<b>REFERRED BY</b>	:	REGI	STRATION DATE	: 07/Sep/2024 10:26 AM	
BARCODE NO.	: 12504544	COLL	ECTION DATE	: 07/Sep/2024 10:37AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE I	INSTITUTE <b>REPO</b>	RTING DATE	: 07/Sep/2024 01:36PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD	, AMBALA CITY - HARYAN	A		
Test Name		Value	Unit	Biological Reference interval	
	CLI	INICAL CHEMISTRY	BIOCHEMISTR	Y	
		LIPID PROFILE	: BASIC		
CHOLESTEROL TOTA by CHOLESTEROL O		194.55	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.	
TRIGLYCERIDES: SEF by GLYCEROL PHOSI	RUM PHATE OXIDASE (ENZYMATIC)	113.19	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0	
HDL CHOLESTEROL by SELECTIVE INHIBIT		47.37	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0	
LDL CHOLESTEROL: by CALCULATED, SPI	SERUM ECTROPHOTOMETRY	124.54	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLESTI by CALCULATED, SP	EROL: SERUM ECTROPHOTOMETRY	147.18 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189. HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0	
	: SERUM ectrophotometry	22.64	mg/dL	0.00 - 45.00	
TOTAL LIPIDS: SERU		502.29	mg/dL	350.00 - 700.00	
CHOLESTEROL/HDL		4.11	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0	
		2.63	RATIO	LOW RISK: 0.50 - 3.0	

**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT

HIGH RISK: > 6.0

3.00 - 5.00

RATIO

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. SUDESH KUMAR			
AGE/ GENDER	: 43 YRS/MALE	PATIENT ID	: 1605013	
<b>COLLECTED BY</b>	:	<b>REG. NO./LAB NO.</b>	: 122409070011	
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 07/Sep/2024 10:26 AM	
BARCODE NO.	: 12504544	<b>COLLECTION DATE</b>	: 07/Sep/2024 10:37AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	: 07/Sep/2024 01:36PM	
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA			
Test Name	Value	Unit	Biological Reference interval	
by CALCULATED, SPE	CTROPHOTOMETRY		MODERATE RISK: 3.10 - 6.0	

## **TRIGLYCERIDES/HDL RATIO: SERUM** by CALCULATED, SPECTROPHOTOMETRY **INTERPRETATION:**

1. Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 wears with a threat the line total should be screened for lipid status.

2.39<sup>L</sup>

age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 



A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

AGE/ GENDER	: 43 YRS/MALE	PATIE	NT ID	: 1605013	
COLLECTED BY	:	REG. N	O./LAB NO.	: 122409070011	
REFERRED BY	:	REGIST	FRATION DATE	: 07/Sep/2024 10:26 AM	
BARCODE NO.	: 12504544	COLLE	CTION DATE	: 07/Sep/2024 10:37AM	
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITU		TING DATE	: 07/Sep/2024 01:36PM	
CLIENT ADDRESS			IIII DAIL	. 07/ Sep/ 2024 01.30FW	
LIENI ADDRESS	: NASIRPUR, HISSAR ROAD, AMBA	ALA CITT - HARTANA			
Test Name		Value	Unit	Biological Refere	ence interval
		ENDOCRINO	OGY		
	THYROI	ENDOCRINOI D STIMULATING H		)	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAN	D STIMULATING H 2.57		0.35 - 5.50	
	NG HORMONE (TSH): SERUM esc <i>ent microparticle immunoassa</i> ) <b>rasensitive</b>	D STIMULATING F 2.57 Y)	<b>IORMONE (TSH)</b> μIU/mL	0.35 - 5.50	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI	NG HORMONE (TSH): SERUM escent microparticle immunoassa) rasensittve AGE	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE (	0.35 - 5.50 (μIU/mL)	
by CMIA (CHEMILUMIN Brd GENERATION, ULT) INTERPRETATION:	NG HORMONE (TSH): SERUM escent microparticle immunoassa) rasensittve AGE 0 – 5 days	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20	0.35 - 5.50 (µlU/mL)	
by CMIA (CHEMILUMIN Brd GENERATION, ULT) INTERPRETATION:	NG HORMONE (TSH): SERUM escent microparticle immunoassa) rasensittve AGE	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00	0.35 - 5.50 (µlU/mL)	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSA RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20	0.35 - 5.50 (µlU/mL)	
by CMIA (CHEMILUMIN Brd GENERATION, ULT) INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAY RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40	0.35 - 5.50 (µlU/mL)	
by CMIA (CHEMILUMIN Brd GENERATION, ULT) INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAN RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months 1 – 5 Years	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40 0.70 – 7.00	0.35 - 5.50	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAN RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months 1 – 5 Years 6 – 10 Years 11 - 15 > 20 Years (Adults)	D STIMULATING H 2.57 y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40 0.70 – 7.00 0.60 – 5.50	0.35 - 5.50	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAN RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months 1 – 5 Years 6 – 10 Years 11 - 15 > 20 Years (Adults)	D STIMULATING F 2.57 Y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40 0.70 – 7.00 0.60 – 5.50 0.50 – 5.50 0.27 – 5.50	0.35 - 5.50	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAY RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months 1 – 5 Years 6 – 10 Years 11 - 15 > 20 Years (Adults) PR 1st Trimester	D STIMULATING H 2.57 y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40 0.70 – 7.00 0.60 – 5.50 0.50 – 5.50 0.27 – 5.50 0.10 - 3.00	0.35 - 5.50	
by CMIA (CHEMILUMIN Brd GENERATION, ULTI INTERPRETATION:	NG HORMONE (TSH): SERUM ESCENT MICROPARTICLE IMMUNOASSAN RASENSITIVE AGE 0 – 5 DAYS 6 Days – 2 Months 3 – 11 Months 1 – 5 Years 6 – 10 Years 11 - 15 > 20 Years (Adults)	D STIMULATING H 2.57 y)	HORMONE (TSH) μIU/mL EFFERENCE RANGE ( 0.70 – 15.20 0.70 – 11.00 0.70 – 8.40 0.70 – 7.00 0.60 – 5.50 0.50 – 5.50 0.27 – 5.50	0.35 - 5.50	

1. Primary or untreated hypothyroidism, may vary from 3 times to more than 100 times normal depending on degree of hypofunction.

2. Hypothyroid patients receiving insufficient thyroid replacement therapy.

3. Hashimotos thyroiditis.

4.DRUGS: Amphetamines, lodine containing agents and dopamine antagonist.

5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge.

DECREASED LEVELS:

1. Toxic multi-nodular goitre & Thyroiditis.

2. Over replacement of thyroid harmone in treatment of hypothyroidism.

3. Autonomously functioning Thyroid adenoma

4.Secondary pituatary or hypothalmic hypothyroidism

5. Acute psychiatric illness

6.Severe dehydration.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

## NOT VALID FOR MEDICO LEGAL PURPOSE

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600, REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



NAME	: Mr. SUDESH KUMAR		
AGE/ GENDER	: 43 YRS/MALE	PATIENT ID	: 1605013
COLLECTED BY	:	REG. NO./LAB NO.	: 122409070011
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 07/Sep/2024 10:26 AM
BARCODE NO.	: 12504544	<b>COLLECTION DATE</b>	: 07/Sep/2024 10:37AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	: 07/Sep/2024 01:36PM
CI LENT ADDDECC	NACIDDUD HICCAD DOAD AMDALA CITY	IIA DVA NA	

A PIONEER DIAGNOSTIC CENTRE © 0171-2532620, 8222896961 ⊠ pkrjainhealthcare@gmail.com

 CLIENT CODE.
 : P.K.R JAIN HEALTHCARE INSTITUTE
 REPORTING DATE
 : 07/Sep/2024 01:36PM

 CLIENT ADDRESS
 : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA
 : 07/Sep/2024 01:36PM

 Test Name
 Value
 Unit
 Biological Reference interval

7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis. 8.Pregnancy: 1st and 2nd Trimester

## LIMITATIONS:

1.TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy. 2.Autoimmune disorders may produce spurious results.

\*\*\* End Of Report \*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600, REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)

